Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 156 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NF7IO3FEgXSxdH;4bYMhSXO|YYm= M2ryeFUxKM7:TR?= NH;RS2M1QCCq NH7lV5JFVVOR NFrFT5VMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm MVmxNFQ6QTZ2Mx?=
OVCA 429 NYjac2pjTnWwY4Tpc44hSXO|YYm= MXuzNFAhdk1? MVW0PEBp M1TxUGROW09? MlfPSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz NXfEO3g5OTB7OUm3OlY>
RPMI8226 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xNFAhdk1? NGf3NmU1QCCq MXLEUXNQ NH\ZZ2xKSzVyPUOwJI5O MXSxNVMxPjR6OR?=
Dox40 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HubFExOCCwTR?= M4jxUlQ5KGh? MUfEUXNQ M4C1VWlEPTB;NECgcm0> NEnqeJcyOTNyNkS4PS=>
MR20 NISyW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfBNVAxKG6P NWLH[oxvPDhiaB?= M4nTcmROW09? M1XaU2lEPTB;MkCgcm0> MnfFNVE{ODZ2OEm=
LR5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7oN|Y5OTByIH7N MofFOFghcA>? M4rOUGROW09? NE[0dppKSzVyPUKwJI5O NIq4fG4yOTNyNkS4PS=>
U266 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPwdZpDOTByIH7N M3zKelQ5KGh? NXHoXFdLTE2VTx?= MVrJR|UxRTNibl2= MYWxNVMxPjR6OR?=
IM-9 NXLsVG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGToTVYyODBibl2= M2fQW|Q5KGh? NHO5e2RFVVOR MXHJR|UxRTZibl2= MXOxNVMxPjR6OR?=
Hs Sultan Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnSbpJrOTByIH7N NXL4OIdbPDhiaB?= M4HuVWROW09? MofPTWM2OD1{MDDuUS=> NGeyUIwyOTNyNkS4PS=>
PAM-LY2 M4HGcGZ2dmO2aX;uJGF{e2G7 Ml\3NVAxKG6P NWfGXndIOTJiaB?= M4LZWGROW09? NGDiXXdKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=> M2r6PVEyOzVyOUGz
PAM 212 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnNephwOTByIH7N NY[2Xog6PzJiaB?= NG\KVmlFVVOR M2XlXGlvcGmkaYTzJINmdGxidnnhZoltcXS7 MYqxNVM2ODlzMx?=
PAM-LY2 NUfMVJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DidVExOCCwTR?= NWr2OnI2PzJiaB?= NWGwN3RyTE2VTx?= NIDXRZhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MWqxNVM2ODlzMx?=
B4B8 NH3JPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX0RVYyODBibl2= MYO3NkBp NUnVenVlTE2VTx?= MWLJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MkXsNVE{PTB7MUO=
B7E3 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vu[VExOCCwTR?= M2XIclczKGh? M1jUOmROW09? MoXwTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MlX4NVE{PTB7MUO=
UM-SCC-9 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7hUmdPOTByIH7N MUm3NkBp MWTEUXNQ MWTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXWxNVM2ODlzMx?=
UM-SCC-11B NFPUPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDGNVAxKG6P MXS3NkBp M3nQWmROW09? NET0bo1KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MWCxNVM2ODlzMx?=
H460 MonMSpVv[3Srb36gRZN{[Xl? NF;DUJUyOCEQvF2= MWmyOEBp M4fJT2ROW09? MU\JcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 MmrYNVI1QTJzMUe=
U266 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[1NFAhdmdxbXy= NX3hdYY{PDhiaB?= MULEUXNQ NFrqcHhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NWnycHFsOTJ4M{G2NVk>
ARH77 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn2OVAxKG6pL33s NI\1XpM1QCCq Mo\DSG1UVw>? NWTGZm1LUW6qaXLpeJMh[2WubDDndo94fGh? MlzRNVI3OzF4MUm=
WAD-1 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH6ZYs2ODBibnevcYw> MVq0PEBp MnnaSG1UVw>? NU\HbpV1UW6qaXLpeJMh[2WubDDndo94fGh? NGPsWHkyOjZ|MU[xPS=>
U266/LR7 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HmOVUxOCCwZz;tcC=> NGH2b5Q1QCCq MUHEUXNQ NXz6S3BZUW6qaXLpeJMh[2WubDDndo94fGh? NIT2fZYyOjZ|MU[xPS=>
U266/dox4 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;WOVAxKG6pL33s NXzmbmd7PDhiaB?= NIKyXWZFVVOR MVvJcohq[mm2czDj[YxtKGe{b4f0bC=> NFPPc2YyOjZ|MU[xPS=>
RPMI8226/LR5 NWjhTGN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37w[FUxOCCwZz;tcC=> NHfIZ|U1QCCq M1O4bGROW09? MYrJcohq[mm2czDj[YxtKGe{b4f0bC=> NU[2fGxpOTJ4M{G2NVk>
H460 NVjQW|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHBRYU4OTBizszN MXq3NkBp NF2xXGtFVVOR NYPiWZF5UUN3ME2xNFAhdk1? MWOxNlY{OTZ{MB?=
H358 NVPFUHE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrDZ5MyOCEQvF2= M2eweFczKGh? NHzETI1FVVOR NU\mWW12UUN3ME23NEBvVQ>? NIHlW|MyOjZ|MU[yNC=>
H322 NV7W[4RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LoZ|ExKM7:TR?= MWG3NkBp NELTRWRFVVOR M4n4S2lEPTB;NkKwJI5O NXPSOZk5OTJ4M{G2NlA>
H460 NXTaclBjTnWwY4Tpc44hSXO|YYm= NHmwT4syODBibl2= NVj2cplJOjRiaB?= MmPvSG1UVw>? MoD2TY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? MmjFNVI3OzF4MkC=
LNCap-Pro5 MoG0SpVv[3Srb36gRZN{[Xl? MoTaNUDPxE1? NHzBUlA1KGh? MXzEUXNQ M4j1OnN1[WKrbHn6[ZMheDV| MoXyNVQ3OTJ3M{K=
T29 NH;ZOFJCeG:ydH;zbZMhSXO|YYm= MV61NEBvVQ>? NE\YSJo1QCCqIB?= MlH0SG1UVw>? MoX5TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlfONVY4PzhzN{m=
T29Kt1 M2TKVWFxd3C2b4Ppd{BCe3OjeR?= M1PqO|UxKG6P M1TkXFQ5KGhi M3PSe2ROW09? M4fhc2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{i5NVE3Pzd6MUe5
HCT116 NYHFblNKSXCxcITvd4l{KEG|c3H5 MnjMOVAhdk1? NUnEeVBtPDhiaDC= NX3JV|dQTE2VTx?= M4HzcWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml3uNVY4PzhzN{m=
HKe-3 MlrnRZBweHSxc3nzJGF{e2G7 M{XGc|UxKG6P MY[0PEBpKA>? M2XCdGROW09? NF\qflFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYrvW404OTZ5N{ixO|k>
NB-1691 NIXXb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKzVowyKM7:TR?= MUK3NkBp MYnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? NHvYWFQyPzZ6OU[4OC=>
CHLA-255 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK3dmIyKM7:TR?= M37jV|czKGh? NGLpZplKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NFnvOHQyPzZ6OU[4OC=>
SK-N-AS MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLjcINTOSEQvF2= NFvwOlY4OiCq MnzRTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= M{HqPVE4Pjh7Nki0
NB-1691 MXjGeY5kfGmxbjDBd5NigQ>? MYOxNEBvVQ>? MV6yOEBp NFzUdmVUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm NIn6XZQyPzZ6OU[4OC=>
CHLA-255 MoOwSpVv[3Srb36gRZN{[Xl? M1j1PVExKG6P M4DwbFI1KGh? MWDNc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NGjqU44yPzZ6OU[4OC=>
RPMI 8226 Mn;hSpVv[3Srb36gRZN{[Xl? NVnqS5R2OjBibl2= NILRO|Y5KGh? MWPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NUXt[JczOTl2M{[wOVA>
MM.1S M2LVRmZ2dmO2aX;uJGF{e2G7 MVGyNEBvVQ>? MkCzPEBp NEK5RW9UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M3nkfVE6PDN4MEWw
U266 NGX6[lhHfW6ldHnvckBCe3OjeR?= MmPONlAhdk1? M3rRflghcA>? MWXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MWGxPVQ{PjB3MB?=
OPM1 Ml6xSpVv[3Srb36gRZN{[Xl? M1[yRlIxKG6P NYrseVh5QCCq NHzwUJVUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NXHzNnVDOTl2M{[wOVA>
INA6 Mof6SpVv[3Srb36gRZN{[Xl? NX7rWnh1OjBibl2= Mk\yPEBp NFrLenlUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MoXTNVk1OzZyNUC=
OPM2 M3TtWWZ2dmO2aX;uJGF{e2G7 MWiyNEBvVQ>? NH32NGc5KGh? NIHNeolUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MXWxPVQ{PjB3MB?=
RPMI 8226 MkPESpVv[3Srb36gRZN{[Xl? NIOx[lgzOCCwTR?= MXu4JIg> M{WyPGlv\HWlZYOgSG5CKHO7boTo[ZNqew>? M3\pb|E6PDN4MEWw
BaF/3 M4f0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rtbVExOCCwTR?= Moi3OFghcA>? NVrYNY1rUUN3ME22MlIhdk1? M{LLWFIxOzB3Nkmy
BaF/3-p210 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW5NVAxKG6P NXn0Xmp{PDhiaB?= MUnJR|UxRTRwNzDuUS=> NVu2WIFzOjB|MEW2PVI>
TCC-S MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nCdFExOCCwTR?= MYm0PEBp M1;HT2lEPTB;Mj64JI5O MoXvNlA{ODV4OUK=
BaF/3 NX3oPVkyTnWwY4Tpc44hSXO|YYm= MnXjOkBvVQ>? MUm0PEBp NF:xcHpKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MYmyNFMxPTZ7Mh?=
BaF/3-p210 MU\GeY5kfGmxbjDBd5NigQ>? NH\hT|Y3KG6P NIjyOGg1QCCq NITReIZKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 NXvi[nRUOjB|MEW2PVI>
BaF/3-p210 Mk\kSpVv[3Srb36gRZN{[Xl? M{nnUlYhdk1? MkP2NlQhcA>? MXjS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? NXP2PYQ6OjB|MEW2PVI>
Raji MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HCclEh|ryP MVuyOEBp MV7S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M1XGZlIyOTdyOUi4
LCL-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvmbZQ{OSEQvF2= NF3VWZMzPCCq MULS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NFvxfVYzOTF5MEm4PC=>
LCL-2 NFHSfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUNUDPxE1? M1jIelI1KGh? MnTaVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MV6yNVE4ODl6OB?=
BJAB NYLWZlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\iNUDPxE1? NIC1b3YzPCCq NF;0XmpT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MWKyNVE4ODl6OB?=
SNT-13 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknsNUDPxE1? Mmr1NlQhcA>? NXPBfmhJWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NIDJbJMzOTF5MEm4PC=>
SNT-16 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixJO69VQ>? NHHWVHAzPCCq NULVTHFpWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M{PCc|IyOTdyOUi4
Jurkat M3mzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexJO69VQ>? MWeyOEBp NWjLenRoWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MnX4NlEyPzB7OEi=
KAI-3 NWLwdWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PPdFEh|ryP NXr1Z3Q4OjRiaB?= M3jB[nJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUCyNVE4ODl6OB?=
SNK-6 M{H0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjYZWxFOSEQvF2= MlvmNlQhcA>? M1[2V3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MWCyNVE4ODl6OB?=
KHYG-1 M1nMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7YNUDPxE1? NGjGdYszPCCq NWrG[4tXWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MoPINlEyPzB7OEi=
SNT-16 M2DrdWFxd3C2b4Ppd{BCe3OjeR?= NVzEOVl7OSEQvF2= MmTqOkBp NIfMNIFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEe3N|IzOTF5MEm4PC=>
Jurkat NHrFXYtCeG:ydH;zbZMhSXO|YYm= MlTpNUDPxE1? MmmxOkBp M{XzV2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3XNblIyOTdyOUi4
KAI-3 MlHzRZBweHSxc3nzJGF{e2G7 NWC5Xok5OSEQvF2= NF\hTo83KGh? MkLrTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NIXnUJQzOTF5MEm4PC=>
KHYG-1 NWq1dJBnSXCxcITvd4l{KEG|c3H5 MnXBNUDPxE1? MnjJOkBp MlPlTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MmHmNlEyPzB7OEi=
SNT-13 NXe3WVBCSW62aY\pdoFtKEG|c3H5 M3nsSVEh|ryP M1vaWFI1KGh? MVrJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NVOzZYs3OjFzN{C5PFg>
SNT-16 NY\uNlYzSW62aY\pdoFtKEG|c3H5 MXWxJO69VQ>? MVWyOEBp NEfFS2JKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MnG5NlEyPzB7OEi=
KAI-3 MWXBcpRqfmm{YXygRZN{[Xl? M2PDPVEh|ryP MljxNlQhcA>? NWfUc3JiUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M4[4Z|IyOTdyOUi4
SNK-6 NF\P[lZCdnSrdnnyZYwhSXO|YYm= NHTiR|IyKM7:TR?= NUXVWlduOjRiaB?= M{f6cWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MnrWNlEyPzB7OEi=
RAW 264.7 NFjwW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFznTnUyODBibl2= M1m4TVQ5KGh? M1nRd3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MX2yNlQzPzF3NB?=
A375 MXLBdI9xfG:|aYOgRZN{[Xl? NF3VZmMyOCCwTR?= NEj4OIYzPCCq M1XzT2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGrzXJczOzB5OUC4Ny=>
BLM MnnjRZBweHSxc3nzJGF{e2G7 MoftNVAhdk1? NGjVcXkzPCCq NX7OTJYyUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NX70WYg6OjNyN{mwPFM>
A375 NHnwZ5dCfXSxcHjh[5khSXO|YYm= NYeyS4g3OTBibl2= NH3DelcyOiCq M2f6[Glv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M13oOFI{ODd7MEiz
BLM NVyxPGRmSXW2b4DoZYd6KEG|c3H5 MXGxNEBvVQ>? MWexNkBp NU[2T495UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NYTrSFEzOjNyN{mwPFM>
H1299 MkXQRZBweHSxc3nzJGF{e2G7 M1nv[FgxKG6P M{LyOFI1KGh? MYjEUXNQ M4HhNXNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| M2iwdlI2OzJ|Nkmz
Hut-78 MXjGeY5kfGmxbjDBd5NigQ>? NUDKZWtbOTByIH7N MUGyOEBp M4K5ZWROW09? NYjYc5FsTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;u MlT2NlU3QDF|M{W=
H9 MkjHSpVv[3Srb36gRZN{[Xl? MnjzNVAxKG6P MlzFNlQhcA>? MWnEUXNQ NYW0ZlUyTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u MnLnNlU3QDF|M{W=
HH MXrGeY5kfGmxbjDBd5NigQ>? MmTJNVAxKG6P MVeyOEBp MXXEUXNQ MWHkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? NWfpbpk1OjV4OEGzN|U>
Hut-78 NYLIbGg5VWmpcnH0bY9vKEG|c3H5 M{fTW|ExOCCwTR?= NFzjb5czPCCq NELEenhFVVOR MUnS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn NInYc|czPTZ6MUOzOS=>
HH Ml24UYloemG2aX;uJGF{e2G7 MUmxNFAhdk1? NV3ZcHhrOjRiaB?= NUOwNVY6TE2VTx?= MmDjVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= Ml6xNlU3QDF|M{W=
U937 MXHGeY5kfGmxbjDBd5NigQ>? M4jTXFExOCCwTR?= NVzsW3NtPiCq MmXmTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? NWTsU2FCOjV5OUG0O|c>
human PBMC MXLGeY5kfGmxbjDBd5NigQ>? MnvZNVAxKG6P MX:yOEBp MYHJcoR2[2W|IFnMMVghemWuZXHz[S=> MWmyOVc6OTR5Nx?=
ES6 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGzVXlKSzVyPUCuNFAzOSCwTR?= NXT2Z|VwW0GQR1XS
SK-UT-1 M3Pa[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrzfGNOUUN3ME2wMlE3OyCwTR?= NIXYTnlUSU6JRWK=
SH-4 NFnucJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMUezJI5O NH3LW|ZUSU6JRWK=
TE-9 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPQPHRRUUN3ME2wMlE5OiCwTR?= NYL5WFlRW0GQR1XS
A253 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMkC4JI5O NGHwOmFUSU6JRWK=
no-10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTJZ2x5UUN3ME2wMlIyKG6P MYTTRW5ITVJ?
MMAC-SF NHPrXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m1XGlEPTB;MD6yNVYhdk1? MYHTRW5ITVJ?
A101D NXLYOI1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7UVpFPUUN3ME2wMlIzPSCwTR?= M{GxbXNCVkeHUh?=
NTERA-S-cl-D1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\BfGlEPTB;MD6yOFMhdk1? NWjyRXRQW0GQR1XS
8-MG-BA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMkWgcm0> Mo\NV2FPT0WU
KNS-42 M13tO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13SV2lEPTB;MD6yOVghdk1? NI\ENWtUSU6JRWK=
LXF-289 NGPSZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrOTWM2OD1yLkK2PUBvVQ>? MnzkV2FPT0WU
OVCAR-4 M2Tkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHyOoVKSzVyPUCuNlg6KG6P M3\vbXNCVkeHUh?=
LOUCY NUHyXWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMkmzJI5O NVm4dHdtW0GQR1XS
BB65-RCC NXroTGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHTOnpHUUN3ME2wMlMxPCCwTR?= Mlv1V2FPT0WU
D-542MG Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XVe2lEPTB;MD6zNlkhdk1? NV;HOnBUW0GQR1XS
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwM{Ogcm0> NULwUHpUW0GQR1XS
BB30-HNC NWLMdIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\GTWM2OD1yLkOzOUBvVQ>? NU\LdWtKW0GQR1XS
KS-1 M{L3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[xTWM2OD1yLkO0JI5O NYmx[2J1W0GQR1XS
A388 M{myXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK5TWM2OD1yLkO1OkBvVQ>? NWjOeFVxW0GQR1XS
ES8 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHvT|hKSzVyPUCuOEBvVQ>? Mm[5V2FPT0WU
MZ2-MEL M4qzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwNEC3JI5O NUXaWYtGW0GQR1XS
HCC2998 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwNEGyJI5O MULTRW5ITVJ?
D-247MG NELmTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;UWlVKSzVyPUCuOFE{KG6P MUHTRW5ITVJ?
ACN NYPGRWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNEG3JI5O M3H6fnNCVkeHUh?=
LB2518-MEL MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwNEK1JI5O NILOXGlUSU6JRWK=
ES1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNEOgcm0> M1nDR3NCVkeHUh?=
HCE-T Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfIWWlHUUN3ME2wMlQ{QSCwTR?= MlzTV2FPT0WU
OS-RC-2 NIHkSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LVSWlEPTB;MD60OEBvVQ>? MnnUV2FPT0WU
MFH-ino MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz6dotKSzVyPUCuOFQ{KG6P MkjKV2FPT0WU
OCUB-M MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITHNmhKSzVyPUCuOFQ4KG6P NHTaNWFUSU6JRWK=
CP66-MEL M2\hW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD6TWM2OD1yLkS3N{BvVQ>? M3zWSXNCVkeHUh?=
LB771-HNC NXq5eIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwNEe0JI5O MWPTRW5ITVJ?
DSH1 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\ucmlEPTB;MD60PEBvVQ>? NGDBbpRUSU6JRWK=
HUTU-80 M4rJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\FXGlEPTB;MD61N|Mhdk1? MUHTRW5ITVJ?
CESS MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwNUO4JI5O M{m3e3NCVkeHUh?=
NCI-H747 NG\nRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjTWM2OD1yLkWzPUBvVQ>? M1LEenNCVkeHUh?=
HT-144 M1jEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwNUe2JI5O MnLSV2FPT0WU
COLO-829 NVfFblg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPPTWM2OD1yLk[xOEBvVQ>? MWXTRW5ITVJ?
A4-Fuk MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLkTWM2OD1yLk[yN{BvVQ>? Mn7vV2FPT0WU
GI-ME-N NYTjN2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFewT2hKSzVyPUCuOlM1KG6P MXHTRW5ITVJ?
LB831-BLC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofQTWM2OD1yLk[0NUBvVQ>? MXTTRW5ITVJ?
HOP-62 M3PQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVruco1XUUN3ME2wMlY1PyCwTR?= NWDacHppW0GQR1XS
BB49-HNC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHFTWM2OD1yLk[1NkBvVQ>? MV;TRW5ITVJ?
D-336MG M2f4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNkW3JI5O NVm4TnRTW0GQR1XS
TK10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;ETWM2OD1yLk[3PUBvVQ>? M1frZnNCVkeHUh?=
Ramos-2G6-4C10 NHTubpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjmV2pKSzVyPUCuOlk{KG6P NX3mZ4NYW0GQR1XS
LB373-MEL-D M2fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPIZpdLUUN3ME2wMlchdk1? NUHuTnJ{W0GQR1XS
SF126 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zUOWlEPTB;MD63NFEhdk1? NGT0OpFUSU6JRWK=
UACC-257 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLHTWM2OD1yLkexJI5O M4\XSHNCVkeHUh?=
KINGS-1 NFHTUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF75cGRKSzVyPUCuO|IzKG6P MnTtV2FPT0WU
LS-513 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Doc2lEPTB;MD63N|khdk1? NUmzOpJjW0GQR1XS
GI-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17iTWlEPTB;MD63OlQhdk1? NX3iVVZxW0GQR1XS
ES7 M1\1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\1OmlEPTB;MD63OlYhdk1? MnTqV2FPT0WU
LB2241-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwOEC0JI5O M1Tpb3NCVkeHUh?=
D-263MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwOEC3JI5O NHG2O2lUSU6JRWK=
SW684 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwOEKxJI5O MlnTV2FPT0WU
ML-2 M176V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz1bGdKSzVyPUCuPFIyKG6P MXHTRW5ITVJ?
SK-LMS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TKTGlEPTB;MD64OVQhdk1? NGHKTFdUSU6JRWK=
TE-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvXTWM2OD1yLki2OUBvVQ>? M2LEZnNCVkeHUh?=
QIMR-WIL NXH4RYd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\IUXFKSzVyPUCuPFg6KG6P M4PSOnNCVkeHUh?=
NCI-H1355 NVvBe3o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG1N|hKSzVyPUCuPFk2KG6P M2LV[nNCVkeHUh?=
SNB75 M{XmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ZfndKSzVyPUCuPVEzKG6P MYHTRW5ITVJ?
RXF393 NHjNV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHLSnhKSzVyPUCuPVE1KG6P MUfTRW5ITVJ?
IST-MEL1 NELuRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXHTWM2OD1yLkmxO{BvVQ>? MVPTRW5ITVJ?
SF268 NGXKWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr5T|RNUUN3ME2wMlkzOyCwTR?= NGjvZYNUSU6JRWK=
KALS-1 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3SmZKSzVyPUCuPVI2KG6P NGi5[YhUSU6JRWK=
HC-1 M2TTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ZV2gzUUN3ME2wMlk4PSCwTR?= MmP3V2FPT0WU
SW872 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;4TWM2OD1yLkm5OkBvVQ>? NHzhNYVUSU6JRWK=
PSN1 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTLeZlKSzVyPUGuNFEhdk1? M1HaSHNCVkeHUh?=
TE-1 NHXob3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i5dWlEPTB;MT6wN{BvVQ>? NXKw[VMzW0GQR1XS
TE-10 NXLnUoNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HQO2lEPTB;MT6wN{BvVQ>? MUHTRW5ITVJ?
RKO NXXsUHN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ZVWlEPTB;MT6wOkBvVQ>? MYTTRW5ITVJ?
LC-2-ad NFvuXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TjdWlEPTB;MT6wPEBvVQ>? M3vwOHNCVkeHUh?=
SK-MM-2 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX31R2V5UUN3ME2xMlA6KG6P NXr2eHBJW0GQR1XS
VA-ES-BJ MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInKNFVKSzVyPUGuNFkhdk1? MVzTRW5ITVJ?
MZ7-mel NXHSPZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULW[Y85UUN3ME2xMlA6KG6P NUX0O3ByW0GQR1XS
D-392MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXiTWM2OD1zLkGgcm0> NHLWSnFUSU6JRWK=
CCRF-CEM MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwMUOgcm0> NGnte2RUSU6JRWK=
EM-2 NHXHdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjtd5NGUUN3ME2xMlE3KG6P NUHNRZF3W0GQR1XS
HAL-01 M4Dob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwMUigcm0> NWW3fYdzW0GQR1XS
TE-8 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHuTWM2OD1zLkG5JI5O M1PydHNCVkeHUh?=
NCI-H1882 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMjDuUS=> MVHTRW5ITVJ?
Daudi M{K4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rCXWlEPTB;MT6yNkBvVQ>? MWrTRW5ITVJ?
BL-41 NYLxU5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDqemRKSzVyPUGuNlUhdk1? MmPlV2FPT0WU
SR M3XUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Lm[GlEPTB;MT6yOUBvVQ>? M4\UbHNCVkeHUh?=
KM12 NIrqZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17SV2lEPTB;MT6yO{BvVQ>? M{XhOXNCVkeHUh?=
K5 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwMkigcm0> NXTsNFhlW0GQR1XS
A3-KAW M4r3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;tdWxMUUN3ME2xMlI5KG6P MXfTRW5ITVJ?
CMK MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rie2lEPTB;MT6yPUBvVQ>? NET6S2xUSU6JRWK=
Calu-6 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwMkmgcm0> M2TPd3NCVkeHUh?=
IST-SL2 NFG1ZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Dn[WlEPTB;MT6zNUBvVQ>? M{LhV3NCVkeHUh?=
OPM-2 M2PVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv2TWM2OD1zLkOzJI5O NUXER2hWW0GQR1XS
DU-4475 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrYUlBVUUN3ME2xMlM3KG6P MorZV2FPT0WU
ECC12 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHsfJFKSzVyPUGuN|chdk1? NXy5NWdRW0GQR1XS
L-540 M{\QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDETWM2OD1zLkO3JI5O MYLTRW5ITVJ?
CAS-1 NVe1VIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDndpZtUUN3ME2xMlM4KG6P MX7TRW5ITVJ?
PF-382 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwNEegcm0> NYGwTo1EW0GQR1XS
LS-411N MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zx[2lEPTB;MT61N{BvVQ>? NW\ZTpE2W0GQR1XS
NCI-H69 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC3ZlZKSzVyPUGuOVQhdk1? MUDTRW5ITVJ?
NB12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fLdWlEPTB;MT61OkBvVQ>? M3n4OnNCVkeHUh?=
HEL Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVTWM2OD1zLk[xJI5O NWDNW5l3W0GQR1XS
GCIY MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX2TWM2OD1zLk[yJI5O NUDmXJA6W0GQR1XS
EHEB NHHRclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwNkegcm0> M4PKfHNCVkeHUh?=
TGBC1TKB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW2cGF3UUN3ME2xMlcyKG6P NW[yOGw2W0GQR1XS
KURAMOCHI M{fxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwN{Kgcm0> NUfyTYRlW0GQR1XS
U-266 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfvTWM2OD1zLke2JI5O NFTTfoVUSU6JRWK=
LC4-1 NIm2VWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTyZZk3UUN3ME2xMlc6KG6P NIK1WlBUSU6JRWK=
NCI-H2126 NWjNcplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z3PWlEPTB;MT64JI5O NUXvWWw{W0GQR1XS
NCI-H1092 NV7WWZo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnITWM2OD1zLkigcm0> M{GzOXNCVkeHUh?=
GB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwOEGgcm0> MmDkV2FPT0WU
MV-4-11 M4\tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjkd5ZKSzVyPUGuPFIhdk1? NF\2fFlUSU6JRWK=
Becker NXjldY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ZOVRKSzVyPUGuPFMhdk1? MXPTRW5ITVJ?
MPP-89 NVjRdWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{joOmlEPTB;MT64PUBvVQ>? MlrEV2FPT0WU
BE-13 NH\tfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nK[mlEPTB;MT65N{BvVQ>? NH7NSYNUSU6JRWK=
697 M4fQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7XTWM2OD1zLkm5JI5O M1PIUnNCVkeHUh?=
NKM-1 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJibl2= NGqwS4RUSU6JRWK=
NB13 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJibl2= Mni1V2FPT0WU
LS-123 Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLDTWM2OD1{LkCyJI5O NVvJZVBuW0GQR1XS
NB17 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX0U5RtUUN3ME2yMlA1KG6P MYjTRW5ITVJ?
LAN-6 M1Ti[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:4fWlEPTB;Mj6wOUBvVQ>? MofuV2FPT0WU
EW-24 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJwMEigcm0> MkTRV2FPT0WU
NOS-1 M1Lp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwMUGgcm0> NI\YN|hUSU6JRWK=
BL-70 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PmS2lEPTB;Mj6xNkBvVQ>? NIS5ZnBUSU6JRWK=
GT3TKB MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17rW2lEPTB;Mj6xNkBvVQ>? NHS0eJBUSU6JRWK=
HH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\NeGlEPTB;Mj6xN{BvVQ>? NXzoRphKW0GQR1XS
KE-37 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HGcWlEPTB;Mj6xN{BvVQ>? MWrTRW5ITVJ?
MOLT-4 M2D6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDzTWtKSzVyPUKuNVMhdk1? NWrkXWU2W0GQR1XS
EKVX MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTnWWVKSzVyPUKuNVQhdk1? NYDRVld3W0GQR1XS
KGN NW\pNJpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLtb2lLUUN3ME2yMlE2KG6P MVTTRW5ITVJ?
ES4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\YNmlEPTB;Mj6xOkBvVQ>? NV;2ZpNvW0GQR1XS
SJSA-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\vTWlEPTB;Mj6yNUBvVQ>? M2LsS3NCVkeHUh?=
KMOE-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DHdGlEPTB;Mj6yN{BvVQ>? NHTEO4VUSU6JRWK=
NB5 NVzKVY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwMkegcm0> Mm\JV2FPT0WU
BC-1 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDjSnJEUUN3ME2yMlMyKG6P MWXTRW5ITVJ?
NB10 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTWTWM2OD1{LkOyJI5O M{j1VnNCVkeHUh?=
RPMI-8226 NGntVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD1[2hKSzVyPUKuN|Uhdk1? MU\TRW5ITVJ?
SCC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwM{egcm0> NUPtS3JsW0GQR1XS
ARH-77 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfwUIVKSzVyPUKuN|ghdk1? MWHTRW5ITVJ?
NCI-H748 NYHnRplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4roUmlEPTB;Mj6zPUBvVQ>? MofFV2FPT0WU
KU812 NGDNU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu3TmZKSzVyPUKuOFIhdk1? M4HLdHNCVkeHUh?=
NCI-H64 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL2RYtKSzVyPUKuOFQhdk1? M1eycnNCVkeHUh?=
NB69 NHLiVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwNE[gcm0> NFvzWlVUSU6JRWK=
KNS-81-FD MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwNEigcm0> NGnxNJJUSU6JRWK=
LB1047-RCC NYXyUZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LvOmlEPTB;Mj61O{BvVQ>? M4\ESXNCVkeHUh?=
EB-3 NX3oSmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwNk[gcm0> NIjLU|lUSU6JRWK=
Mo-T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfBS5lRUUN3ME2yMlc1KG6P MYjTRW5ITVJ?
EW-16 NX3MOJQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJwN{Wgcm0> MnvsV2FPT0WU
CTV-1 NVzHRXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn3fFlDUUN3ME2yMlghdk1? NEX4UJRUSU6JRWK=
ETK-1 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7mfm4xUUN3ME2yMlg1KG6P MXvTRW5ITVJ?
C2BBe1 NF2weYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\PTWM2OD1{Lki5JI5O MYTTRW5ITVJ?
MOLT-16 NXv5ZlZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwOEmgcm0> NWryUpZwW0GQR1XS
SW954 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXqW3dKSzVyPUKuPUBvVQ>? MXjTRW5ITVJ?
HT MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHIW|hKSzVyPUOuNFIhdk1? NX3XdZduW0GQR1XS
KARPAS-299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHUS5ZKSzVyPUOuNFYhdk1? MYTTRW5ITVJ?
MONO-MAC-6 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n5OmlEPTB;Mz6xJI5O NG\MXlRUSU6JRWK=
CGTH-W-1 NV7zZ2p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjWXlM5UUN3ME2zMlEhdk1? NVvzT3V5W0GQR1XS
SK-PN-DW MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1d5dKSzVyPUOuNVQhdk1? M1LwcHNCVkeHUh?=
CW-2 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzrXmRKSzVyPUOuNlEhdk1? NGm1TlZUSU6JRWK=
SK-N-DZ MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwMk[gcm0> M1nCUXNCVkeHUh?=
NEC8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q0dGlEPTB;Mz6zOUBvVQ>? MoLHV2FPT0WU
LB996-RCC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNwNDDuUS=> MVTTRW5ITVJ?
DB NUnXUG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfFN29GUUN3ME2zMlQyKG6P NVX0NmNVW0GQR1XS
TE-15 M4TVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0fGJKSzVyPUOuOFMhdk1? NWnFOZVSW0GQR1XS
COR-L88 NFXBVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK1TYVKSzVyPUOuOFchdk1? M{m1SnNCVkeHUh?=
LAMA-84 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{eyXGlEPTB;Mz60PUBvVQ>? NH3pWppUSU6JRWK=
MEG-01 M{T6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNwNEmgcm0> NFTxcnlUSU6JRWK=
LOXIMVI NGr4[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF63dZNKSzVyPUOuOUBvVQ>? MlTLV2FPT0WU
RPMI-8402 M{\SR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrQTWM2OD1|LkWgcm0> MonjV2FPT0WU
KARPAS-45 NYTGSoFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHVcGNrUUN3ME2zMlU1KG6P M{TObXNCVkeHUh?=
HCC1187 NG[2VVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXXR5NZUUN3ME2zMlU1KG6P M{n6ZnNCVkeHUh?=
MZ1-PC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOwSlRKSzVyPUOuOVQhdk1? MmPKV2FPT0WU
no-11 NWPKb4VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNwNUWgcm0> Mn3NV2FPT0WU
EVSA-T M363PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDabpFoUUN3ME2zMlYhdk1? NF;1TINUSU6JRWK=
DJM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXMTWM2OD1|Lk[zJI5O NID5SIxUSU6JRWK=
COLO-684 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwNk[gcm0> MmH4V2FPT0WU
NMC-G1 NH7JeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7vV3JKSzVyPUOuOlghdk1? MVjTRW5ITVJ?
LC-1F M2HyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfiSoNKSzVyPUOuO|Qhdk1? NVTXSIh5W0GQR1XS
RL95-2 M{nCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvQTWM2OD1|Lke5JI5O MmjvV2FPT0WU
COLO-320-HSR NEDIfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwOUKgcm0> NXzTW29EW0GQR1XS
RCC10RGB M4TvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwOUOgcm0> M3m2[HNCVkeHUh?=
HD-MY-Z MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy2fIdKSzVyPUOuPVMhdk1? MVLTRW5ITVJ?
NCI-H2141 M1m1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwMEWgcm0> MkDQV2FPT0WU
K-562 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTRwMUKgcm0> MlnZV2FPT0WU
NCI-H1648 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrsOpZKSzVyPUSuNVMhdk1? NYDNTWl3W0GQR1XS
OMC-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLrbJlKSzVyPUSuNVghdk1? M3L5[HNCVkeHUh?=
LB647-SCLC M2rHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLJOI9LUUN3ME20MlIzKG6P MX3TRW5ITVJ?
TE-12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwMkWgcm0> MWDTRW5ITVJ?
NOMO-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnGN49KSzVyPUSuN|Mhdk1? MXjTRW5ITVJ?
Raji MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwNE[gcm0> Ml;oV2FPT0WU
NALM-6 NVzzVWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwNEmgcm0> MYfTRW5ITVJ?
HL-60 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnBbXBKSzVyPUSuOlchdk1? MljOV2FPT0WU
IST-SL1 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwNkigcm0> MmfPV2FPT0WU
MHH-PREB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHTb|RKSzVyPUSuPFYhdk1? M3fKbnNCVkeHUh?=
MHH-NB-11 M2ewRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WyOWlEPTB;ND65NUBvVQ>? M1G3SHNCVkeHUh?=
JiyoyeP-2003 NWf4R|d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXqWGtKSzVyPUWgcm0> M3f3VHNCVkeHUh?=
SBC-1 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwMEGgcm0> NVjFToN[W0GQR1XS
CHP-126 NInDd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDIN3NKSzVyPUWuNFYhdk1? NFi4VXlUSU6JRWK=
LU-139 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTVwMUOgcm0> MVrTRW5ITVJ?
NCI-SNU-5 M1zoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\RNpdKSzVyPUWuNVchdk1? M4jQdXNCVkeHUh?=
SW962 NHLwSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\nTGdKSzVyPUWuNlEhdk1? MVzTRW5ITVJ?
EW-1 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfKUZVOUUN3ME21MlMyKG6P NXrwUnhmW0GQR1XS
NCI-H1417 M1LMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjoSFBKSzVyPUWuOVEhdk1? MUHTRW5ITVJ?
LU-65 NUnlXFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP0VplKSzVyPUWuPFQhdk1? NEm5NpFUSU6JRWK=
D-502MG M4fBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETNbYtKSzVyPU[uN|chdk1? MWPTRW5ITVJ?
BC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYTWM2OD14Lk[xJI5O NH2wS2RUSU6JRWK=
GDM-1 NGfQUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzsTWM2OD14Lke3JI5O NWfyXXB7W0GQR1XS
NCI-H2196 NEO1[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\aTJVPUUN3ME22Mlghdk1? MkLuV2FPT0WU
NB1 NHW2U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZwOEigcm0> Mkj5V2FPT0WU
NCI-H345 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDGVItKSzVyPUeuNkBvVQ>? MWLTRW5ITVJ?
SU-DHL-1 NYHhOnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwMkSgcm0> MXjTRW5ITVJ?
JVM-2 M3PxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXMbYxVUUN3ME23MlI5KG6P MVHTRW5ITVJ?
LU-134-A NVTJ[5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7RTWM2OD15LkO5JI5O Ml3uV2FPT0WU
NCI-H1694 M3v6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfwW|lZUUN3ME23MlU5KG6P NHTXZVFUSU6JRWK=
NCI-SNU-16 NITRWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;FWmxKSzVyPUeuOlUhdk1? Mln2V2FPT0WU
L-363 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTdwNzDuUS=> MoHSV2FPT0WU
KG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHRTWM2OD15Lkm0JI5O NWfRNolvW0GQR1XS
MN-60 M4Hxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRThwMUSgcm0> M4j3OHNCVkeHUh?=
NB6 M1nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn5cpZtUUN3ME24MlQ5KG6P M1LFPHNCVkeHUh?=
MLMA NViwPHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonzTWM2OD16Lki1JI5O MnezV2FPT0WU
ATN-1 NYXZRpBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRThwOEmgcm0> NXOwbnE2W0GQR1XS
SK-NEP-1 Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\EOWZIUUN3ME25MlAyKG6P Mmn2V2FPT0WU
DMS-114 NF3ITm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnSWIhKSzVyPUmuOlIhdk1? MmTGV2FPT0WU
CTB-1 M1OyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HKOGlEPTB;OT62O{BvVQ>? Mk\UV2FPT0WU
NCI-H2081 NGGwRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFyLkC5JI5O NVfrXIJHW0GQR1XS
ES5 M1rTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHMTWM2OD1zMD6zPEBvVQ>? M{LoTXNCVkeHUh?=
HCC1599 NVjvd5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFzLkmxJI5O NFLRZm9USU6JRWK=
NCI-H23 NHvEfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHrT3FKSzVyPUGyMlEzKG6P MnqwV2FPT0WU
NCI-H1581 NGW5NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonBTWM2OD1zMj6yPEBvVQ>? M2TNdnNCVkeHUh?=
JVM-3 NXfQbYFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3IUVJ7UUN3ME2xNk46QSCwTR?= NGP6SmZUSU6JRWK=
NCI-SNU-1 M2fEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPNRZFKSzVyPUGzMlE6KG6P MnLzV2FPT0WU
NB7 NWW1e|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\SVGlEPTB;MUWuPVIhdk1? MoL1V2FPT0WU
JAR NGD2WVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF4LkGzJI5O NHfUbolUSU6JRWK=
TGW MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\SVJhKSzVyPUG2MlQ5KG6P MWHTRW5ITVJ?
U-87-MG M1;WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF4Lke2JI5O MkPvV2FPT0WU
NCI-H1436 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1S41KSzVyPUG3MlAyKG6P MUTTRW5ITVJ?
GOTO NYH5O3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL1SXVKSzVyPUG3MlA3KG6P M33L[XNCVkeHUh?=
COLO-800 M1njU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDNNFhvUUN3ME2xO{43PCCwTR?= MX7TRW5ITVJ?
MFM-223 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWzZWhKSzVyPUG3MlkyKG6P MXHTRW5ITVJ?
EW-18 M{Hr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfLTYtKSzVyPUG3Mlk3KG6P MlvIV2FPT0WU
NB14 M2rFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P1UGlEPTB;MUeuPVghdk1? NX\3foRtW0GQR1XS
EB2 NWXEOm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF6LkC4JI5O NYKwW|hWW0GQR1XS
EoL-1- MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLzfHF4UUN3ME2xPE4{OSCwTR?= M4nLe3NCVkeHUh?=
NCCIT NXPMdG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXSdIQ1UUN3ME2xPE4{PiCwTR?= MlrBV2FPT0WU
DG-75 NWDDSlhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\a[|JrUUN3ME2xPE43OSCwTR?= NXTSdnVEW0GQR1XS
HCC2218 M1fCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF7LkWgcm0> MVXTRW5ITVJ?
TE-6 NEHJUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO0TWM2OD1{MD6wPEBvVQ>? MmHFV2FPT0WU
SF539 M{jyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrZ2lEPTB;MkCuOlchdk1? MXHTRW5ITVJ?
NCI-H446 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX0bI1KSzVyPUKxMlE5KG6P MoXKV2FPT0WU
IST-MES1 NHTUcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ{Lke3JI5O MlfnV2FPT0WU
NCI-H82 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ|LkCyJI5O MnX0V2FPT0WU
HCC2157 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfDZ2dJUUN3ME2yN{4yOyCwTR?= NWf4dlNpW0GQR1XS
EW-12 NV3zVXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;JcJhyUUN3ME2yN{4yPyCwTR?= NITj[VdUSU6JRWK=
SIMA MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrVWGx3UUN3ME2yN{4{QCCwTR?= MkLZV2FPT0WU
DOHH-2 M3mwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6zTWM2OD1{Mz60OUBvVQ>? NXv1OWZnW0GQR1XS
IM-9 NEXlZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fCeWlEPTB;MkOuOVQhdk1? MUfTRW5ITVJ?
EC-GI-10 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpSZpKSzVyPUK0MlI{KG6P NITqeHJUSU6JRWK=
HDLM-2 M2riS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnFTWM2OD1{ND61OEBvVQ>? NVLuVIZ3W0GQR1XS
LS-1034 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLZZlc4UUN3ME2yOU44PSCwTR?= MkPJV2FPT0WU
REH MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCb3FKSzVyPUK2MlQyKG6P NW\tVpJuW0GQR1XS
LU-165 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTrTWM2OD1{Nj63NkBvVQ>? NV3zOG54W0GQR1XS
NH-12 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ5Lk[3JI5O MmHoV2FPT0WU
WSU-NHL NXrCdnlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K4cGlEPTB;MkiuN|khdk1? NHXQdWZUSU6JRWK=
ECC4 M{nBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LHc2lEPTB;MkiuO|khdk1? NX;jfJJjW0GQR1XS
OCI-AML2 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSycHVKSzVyPUK5MlY6KG6P MkfhV2FPT0WU
EW-3 M{\BVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\abmRKSzVyPUOwMlU6KG6P MlLxV2FPT0WU
NCI-H526 NEPUZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfU[VNKSzVyPUOyMlU1KG6P NFLieZVUSU6JRWK=
NCI-H719 M1G3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLxe3BTUUN3ME2zOE4{OSCwTR?= MnrLV2FPT0WU
KARPAS-422 M{X6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vMXGlEPTB;M{WuNFQhdk1? MUjTRW5ITVJ?
SK-MEL-1 M2f3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzYTWM2OD1|NT6xO{BvVQ>? M1zScnNCVkeHUh?=
ES3 NFjrZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrZXpg2UUN3ME2zOU4yQSCwTR?= MljyV2FPT0WU
UACC-812 M3;6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN3LkS0JI5O NInkZWxUSU6JRWK=
C8166 M2\tU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LHd2lEPTB;M{WuO{BvVQ>? M4HKVHNCVkeHUh?=
MDA-MB-134-VI NFXRfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrpU|FKSzVyPUO1Mlg4KG6P NHXRUlVUSU6JRWK=
D-283MED MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf2TWM2OD1|Nz63PUBvVQ>? MVXTRW5ITVJ?
SHP-77 NYe3d|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjETWM2OD1|OD6wN{BvVQ>? M2PmZnNCVkeHUh?=
NCI-H2227 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqyTWM2OD12MD60PUBvVQ>? NEHo[YlUSU6JRWK=
SKM-1 M17NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T1dmlEPTB;NEKuOlMhdk1? M{OyUHNCVkeHUh?=
L-428 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPpTWM2OD12Mz64OkBvVQ>? NUG4bWtmW0GQR1XS
RPMI-6666 NWDlcXpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O1WmlEPTB;NEWuPFkhdk1? MXXTRW5ITVJ?
NCI-H716 NWezUY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3FTWM2OD12OD64NUBvVQ>? NVSzfpN1W0GQR1XS
DMS-79 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WxbmlEPTB;NUCuO|Ehdk1? NV7FOG1UW0GQR1XS
RS4-11 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTTTWM2OD13MD64PEBvVQ>? MlHEV2FPT0WU
NCI-H720 NFOyWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PxVGlEPTB;NUGuNVEhdk1? MUDTRW5ITVJ?
MC-CAR NYDEPZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVzLkWyJI5O MlfPV2FPT0WU
TALL-1 NH;ScYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDGTWM2OD13Mz65NUBvVQ>? NUDnVZF{W0GQR1XS
NCI-N87 NUTJcogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3TWM2OD13ND6xPEBvVQ>? M3jKdnNCVkeHUh?=
P30-OHK MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTV2Lk[xJI5O Mn7oV2FPT0WU
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Cb2lEPTB;NkGuNlghdk1? M{[xR3NCVkeHUh?=
YT NWTqbVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3TPIE2UUN3ME22NU45KG6P M3OzTnNCVkeHUh?=
MRK-nu-1 NYTzb2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\xS2lEPTB;NkGuPFIhdk1? M17jSXNCVkeHUh?=
BT-474 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\OOoVKSzVyPU[1JI5O M1nYUnNCVkeHUh?=
NCI-H322M MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPDXnpMUUN3ME22Ok4yOSCwTR?= Ml;vV2FPT0WU
NCI-H128 NYfQbWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnQOYNNUUN3ME23OE44PyCwTR?= MlfvV2FPT0WU
KMS-12-PE NUjYcoZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTd4LkK0JI5O NUfCcHN5W0GQR1XS
KP-N-YS M{Ludmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTGd2RLUUN3ME23Ok44PCCwTR?= MYfTRW5ITVJ?
ALL-PO MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG4TWM2OD15Nz62OkBvVQ>? Mnz5V2FPT0WU
EW-13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTd5Lke2JI5O MlHzV2FPT0WU
EW-11 M4Hjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zHe2lEPTB;N{iuOVIhdk1? NFz6VHFUSU6JRWK=
SK-N-FI M2\0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP3TWM2OD16MD6yJI5O MX;TRW5ITVJ?
CAL-148 NUHFO5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD16MT64OEBvVQ>? MVnTRW5ITVJ?
RL NEPnZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTh4LkC5JI5O NEPDb4NUSU6JRWK=
AM-38 M2fpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfPRY5KSzVyPUi4MlA5KG6P MnK0V2FPT0WU
RH-1 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjpWWpHUUN3ME25PU45PSCwTR?= MoXhV2FPT0WU
NCI-H1770 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P4PGlEPTB;MUCyMlQ6KG6P NXLNUHVOW0GQR1XS
SIG-M5 NXHyNGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrMTWM2OD1zMEWuNFYhdk1? M2\ZOXNCVkeHUh?=
GR-ST NFjI[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\nV5B4UUN3ME2xNVMvOzRibl2= MonIV2FPT0WU
ST486 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFzND6wOkBvVQ>? M1zNe3NCVkeHUh?=
NCI-H1650 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELadHlKSzVyPUGxOU4zQSCwTR?= M13nV3NCVkeHUh?=
MHH-CALL-2 NH;UUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fESmlEPTB;MUG1Mlchdk1? NInHdG1USU6JRWK=
BV-173 M2S0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f0fmlEPTB;MUKyMlcyKG6P MYPTRW5ITVJ?
MC116 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF2OD64OUBvVQ>? MWjTRW5ITVJ?
NCI-H524 NX;lemVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDUXnlKSzVyPUG1PU4yKG6P MlO4V2FPT0WU
SCLC-21H M2fzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\zRWlEPTB;MUW5MlQyKG6P M{Xp[3NCVkeHUh?=
NCI-H1304 NHnrNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2[2lEPTB;MU[5MlIyKG6P NVvRZmdHW0GQR1XS
NCI-H510A MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzEOYRKSzVyPUG4OU4{PyCwTR?= M1HlWHNCVkeHUh?=
NCI-H209 MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi5TWZ6UUN3ME2xPVYvPTJibl2= MUfTRW5ITVJ?
KM-H2 NETpc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknWTWM2OD1zOUeuNFUhdk1? NFfqNohUSU6JRWK=
NCI-H1395 NULjOINOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjMW|VKSzVyPUKxNE4yOyCwTR?= NIH0eYdUSU6JRWK=
NCI-H1155 NEHkR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:0c25KSzVyPUKzNE4{OiCwTR?= MY\TRW5ITVJ?
COR-L279 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy3VZF1UUN3ME2yOVIvOTdibl2= M4rhdHNCVkeHUh?=
NCI-H1299 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJ4MT63NUBvVQ>? MYHTRW5ITVJ?
EW-22 NEHGRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILrZYdKSzVyPUK2N{44PSCwTR?= MV\TRW5ITVJ?
SK-MEL-2 NVXHXZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNUYp3UUN3ME2yPFEvQSCwTR?= MX7TRW5ITVJ?
KASUMI-1 M3zE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXCS3lFUUN3ME2yPFMvODVibl2= MonzV2FPT0WU
NCI-H187 NGXEXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfhOWFKSzVyPUK4O{4xQCCwTR?= M3vMRnNCVkeHUh?=
NCI-H2171 M3P4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{exRmlEPTB;Mki4MlkzKG6P NX7FNXRMW0GQR1XS
LNCaP-Clone-FGC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XCV2lEPTB;Mkm1MlI3KG6P MYTTRW5ITVJ?
NCI-H1522 NInucW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKzV3pRUUN3ME2zNFcvODVibl2= MlfrV2FPT0WU
SCH M{Hz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3hTWM2OD1|MkKuNlIhdk1? M3[3UXNCVkeHUh?=
THP-1 M2O4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Czb2lEPTB;M{KyMlYhdk1? M3vBdnNCVkeHUh?=
SNU-C1 NXXteIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITGb|JKSzVyPUO2Nk4xQSCwTR?= NIHMfpRUSU6JRWK=
CA46 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrDeJFKSzVyPUO3N{43OyCwTR?= NFKy[plUSU6JRWK=
NCI-H1963 NX3OVXRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKeodKUUN3ME2zPFYvOTlibl2= M{nYb3NCVkeHUh?=
DEL NH\EXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmyTWM2OD1|OUGuNlchdk1? NFnLdoNUSU6JRWK=
TUR M4TqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S0cGlEPTB;M{m2MlYyKG6P MV3TRW5ITVJ?
NCI-H226 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq3TWM2OD12MEOuNlMhdk1? M1q2cXNCVkeHUh?=
COLO-668 M1nkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nIOWlEPTB;NECzMlU4KG6P M{OyfnNCVkeHUh?=
CPC-N MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\KPGlEPTB;NECzMlc4KG6P MUfTRW5ITVJ?
NCI-H889 MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2V2t2UUN3ME20OlEvQTJibl2= NGqyOJhUSU6JRWK=
J-RT3-T3-5 M3zxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWy[mZtUUN3ME21N|IvPTdibl2= M4D3XnNCVkeHUh?=
MSTO-211H NUHxS4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTV5ND6yOkBvVQ>? MnG4V2FPT0WU
SCC-15 M1ewXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGxTWM2OD14NkeuOFchdk1? M1nITXNCVkeHUh?=
SUP-T1 NXTYPYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PNcmlEPTB;Nki2MlA1KG6P NV;hW3lpW0GQR1XS
DMS-153 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT5TWM2OD15NE[uPFMhdk1? NWfLb|QyW0GQR1XS
MS-1 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTd3OT60NkBvVQ>? Mn3EV2FPT0WU
TC-YIK M{Di[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf5T25KSzVyPUe4NU4xOSCwTR?= MkfyV2FPT0WU
RPMI-8866 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLn[I9NUUN3ME2xNFA3NjJ6IN88US=> NWDpeIc5W0GQR1XS
KY821 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjsSVk6UUN3ME2xNFM3NjB2IN88US=> NYS1SoZ1W0GQR1XS
P31-FUJ M3TTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFzMUKuO|Uh|ryP M37ie3NCVkeHUh?=
COLO-824 M4LkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\sTWM2OD1zMk[xMlc5KM7:TR?= NHvHOnFUSU6JRWK=
U-698-M NEXOeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzpN3pKSzVyPUKyOlIvOTVizszN MonIV2FPT0WU
TE-441-T MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vKdmlEPTB;MkWyNU44KM7:TR?= MXnTRW5ITVJ?
IMR-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPYTWM2OD1|NEC5MlYzKM7:TR?= NEjxWo5USU6JRWK=
NCI-H1838 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M132e2lEPTB;NEG4Ok4{OiEQvF2= NEfQfHZUSU6JRWK=

... Click to View More Cell Line Experimental Data
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products3

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID